ATHA: Total Utang marang Modal Athira Pharma

Logo perusahaan publik Athira Pharma (ATHA)

Athira Pharma, Inc. (ATHA) is developing neuron regeneration therapies for Alzheimer's disease, targeting the neurodegeneration segment. The company is currently utilizing its accumulated reserves to fund costly research and development, a trend reflected in the price action with the 0.03 indicator. Simultaneously, the business is implementing ESG principles, minimizing its carbon footprint and transitioning to closed-loop water systems at its chemical production facilities to protect the environment.

ATHA - Total Utang marang Modal Athira Pharma ing rentang 04.07.2022 - 12.01.2026

Rincian metrik lan analitis perusahaan Athira Pharma Corp (ATHA)

- rega lan prakiraan konsensus rega:
Bagan rega Athira Pharma|ATHA - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Kapitalisasi pasar Athira Pharma|ATHA - Total Nilai Perusahaan
- indikator kapitalisasi buku:
Nilai Akuntansi saben Saham Athira Pharma|ATHA - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku athira.com|ATHA - Nilai Agregat Aset
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Athira Pharma, Inc.|ATHA - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal Athira Pharma, Inc.|ATHA - Gunggung utang perusahaan|Utang marang nilai buku Athira Pharma|ATHA - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Athira Pharma|Rasio cepet athira.com
- statistik bathi lan rasio pasar:
ATHA - Asil keuangan resik
Analisis dhasar perusahaan:Athira Pharma
Barang utama Athira Pharma Corp

The stability of Athira Pharma, Inc. (ATHA) depends on its ability to fund neurotherapy development without excessive borrowing. The financial leverage ratio (total debt-to-equity) at 0.03 measures the proportion of borrowed resources relative to equity, where low values minimize bankruptcy risks in the event of delayed drug commercialization, while high values signal a critical debt load that reduces the fair value of the shares.

Pesaing langsung

Utang marang Ekuitas Biogen|Rasio Utang marang Ekuitas NBIX (Neurocrine)|Total Utang marang Modal RGC|AXSM - Utang marang Modal|ACADIA Pharmaceuticals - Rasio Total Utang marang Ekuitas|Total Utang marang Modal xenon-pharma.com XENE|VKTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi SUPN (Supernus Pharmaceuticals, Inc.)|Catalyst Pharmaceuticals Inc (CPRX) - Utang marang Ekuitas|Utang marang Modal Denali Corp (DNLI)|HRMY (Harmony Biosciences) - Total Utang marang Modal|Total Utang marang Modal biohavenpharma.com|Rasio Total Utang marang Ekuitas AMLX (Amylyx Pharmaceuticals, Inc.)|Utang Agregat marang Modal TRVI|Total Utang marang Modal PRAX (Praxis Medicines)|Rasio Kabeh Utang marang Dana Pribadi AVXL|CeriBell, Inc. - Total Utang marang Modal|Koefisien Total Utang marang Modal Prothena Corporation PLC PRTA|alector.com (ALEC) - Utang marang Ekuitas|Annexon Biosciences - Rasio Kabeh Utang marang Dana Pribadi|OMER (Omeros Corp) - Total Utang marang Modal|Total Utang marang Modal Neurogene Therapeutics|Rasio Total Utang marang Ekuitas ACIU (AC Immune)|VYGR (voyagertherapeutics.com) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Neumora Therapeutics, Inc. NMRA|SCLX (Scilex Holding) - Utang Agregat marang Ekuitas|Tevogen Bio Holdings, Inc. - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi ACOG (Alpha Cognition)|CGTX: Total Utang marang Modal|inhibikase.com (IKT) - Total Utang marang Modal|Utang marang Ekuitas Cassava Sciences|ASRT: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Coya Therapeutics, Inc. (COYA)|Rasio Total Utang marang Ekuitas vistagen.com VTGN|Total Utang marang Modal OVID (Ovid Therapeutics)|Total Utang marang Modal acumenpharm.com ABOS|CRVO: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi ATHE (Alterity Therapeutics)|CLNN: Total Utang marang Modal|PEPG - Koefisien Total Utang marang Modal|Utang marang Ekuitas Jupiter Neurosciences Inc|Rasio Utang marang Ekuitas RLMD (relmada.com)|Total Utang marang Modal ANVS|Rasio Total Utang marang Ekuitas gracetx.com GRCE|Firefly Neuroscience Inc - Rasio Total Utang marang Ekuitas|Koefisien Total Utang marang Modal ANEW Medical (KLTO)|NeuroSense Therapeutics, Ltd. - Total Utang marang Modal|RVPH - Total Utang marang Modal|MTVA (metaviatx.com) - Rasio Total Utang marang Ekuitas|NRXS: Utang Agregat marang Modal|HSDT (Helius Medical Technologies, Inc.) - Total Utang marang Modal|PASG: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal NEUP|Total Utang marang Modal minervaneurosciences.com (NERV)|Utang marang Ekuitas Addex Therapeutics Ltd ADXN|ALZN: Rasio Utang marang Ekuitas|Cyclerion - Total Utang marang Modal|Utang marang Modal Protagenic Therapeutics|KTTA (pasitheaclinics.com) - Rasio Total Utang marang Ekuitas|Cortigent (CRGT) - Total Utang marang Modal|Utang marang Ekuitas Avenue Therapeutics, Inc.|BCLI: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Cara Therapeutics, Inc (CARA)|CHRO - Utang marang Modal|Total Utang marang Modal ELYM (Eliem Therapeutics Inc.)|Total Utang marang Modal Intra-Cellular Therapies Inc. ITCI|LBPH: Rasio Total Utang marang Ekuitas|Marinus Pharmaceuticals Inc - Utang Agregat marang Modal|NKGN: Total Utang marang Modal|NeuroBo Pharma - Rasio Kabeh Utang marang Dana Pribadi|SAGE (Sage Therapeutics, Inc.) - Total Utang marang Modal|synaptogen.com (SNPX) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Trevena (TRVN)|VIGL (vigilneuro.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal WENA (Anew Medical)|Total Utang marang Modal Cerevel Corp CERE